H.C. Wainwright raised the firm’s price target on Femasys to $13 from $5 and keeps a Buy rating on the shares after the FDA allowed for U.S. commercialization of FemaSeed through the 510(k) pathway. The analyst believes approval of FemaSeed allows the company to initiate launch preparations, and it expects Femasys to begin commercialization in early 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FEMY:
- Femasys expands FemBloc trial enrollment
- Femasys price target raised to $7 from $5 at JonesResearch
- Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
- Femasys gets FDA clearance to market FemaSeed
- Femasys announces first-patient-in for clinical trial of FemBloc